Yesbolatova Aisha, Tominari Yusuke, Kanemaki Masato T
National Institute of Genetics, Research Organization of Information and Systems (ROIS), and Department of Genetics, The Graduate University for Advanced Studies (SOKENDAI), Yata 1111, Mishima, Shizuoka 411-8540, Japan.
FIMECS, Inc., 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan.
Drug Discov Today Technol. 2019 Apr;31:91-98. doi: 10.1016/j.ddtec.2018.11.001. Epub 2018 Nov 24.
Targeted protein degraders, known as proteolysis targeting chimeras (PROTACs), are drawing more attention as next-generation drugs to target currently undruggable proteins. As drug discovery of functional degraders involves time- and cost-consuming laborious processes, we propose employing a ligand-induced genetic degradation system to validate candidate proteins before degrader development. Genetic degradation mimics degrader treatment by depleting a degron-fused protein in the presence of a defined ligand. All genetic systems use a combination of a degron and defined ligand that enables a protein of interest fused with the degron to be recruited to an E3 ubiquitin ligase for ubiquitylation and subsequent degradation by the proteasome. However, these events are based on different principles and have different features. We review the dTAG, HaloTag-based, auxin-inducible degron (AID), and destabilizing domain (DD) systems and discuss a strategy for degrader discovery against novel target proteins.
靶向蛋白质降解剂,即蛋白酶体靶向嵌合体(PROTACs),作为靶向目前难以成药的蛋白质的下一代药物正受到越来越多的关注。由于功能性降解剂的药物研发涉及耗时且成本高昂的繁琐过程,我们建议在降解剂开发之前采用配体诱导的基因降解系统来验证候选蛋白质。基因降解通过在特定配体存在的情况下消耗与降解标签融合的蛋白质来模拟降解剂处理。所有基因系统都使用降解标签和特定配体的组合,使与降解标签融合的目标蛋白质被招募到E3泛素连接酶进行泛素化,随后被蛋白酶体降解。然而,这些事件基于不同的原理且具有不同的特征。我们综述了dTAG、基于卤代标签、生长素诱导降解标签(AID)和不稳定结构域(DD)系统,并讨论了针对新型靶蛋白发现降解剂的策略。